The H.O.P.E. Initiative
Helping Our Protectors Endure
With the onset of Covid-19, in-clinic treatment and programs have become extremely challenging or impossible, so the Nu-Life team immediately accelerated the Remote Treatment Program and began preparing for the changing requirements.
Nu-Life is moving quickly to complete the steps needed to begin treating patients. The H.O.P.E. Initiative was recently launched in order to treat veterans, first responders and health workers suffering from the pain, anxiety, depression and sleeplessness caused directly or indirectly by the Covid-19 crisis. The H.O.P.E. Initiative allows us to mobilize very quickly to prepare to support those who need us, without delay through clinical trail, as Nu-V3 is pre-regulatory clearance.
The H.O.P.E. Initiative will be one of our IRB approved clinical trials. In fact, H.O.P.E. will serve as our flagship Remote Treatment Program, beginning with the treatment of veterans, first responders and healthcare workers, with the intention to expand numbers of these patients as our initial goals are met, quickly followed by additional patient populations suffering from the anxiety, depression and sleeplessness, directly or indirectly resulting from Covid-19. Patients treated in the H.O.P.E Initiative will not be charged and Nu-Life will operate and administrate this initiative as a not-for-profit effort.
Launching the H.O.P.E. Initiative as a remote treatment program allows Nu-Life USA to move quickly to place patients in the treatment pipeline, educate them about Nu-V3 and how the program works. To help facilitate the launch of the initiative as we prepare to provide treatment, we will perform on boarding tasks so there will be no delay in treating patients with Nu-V3 over the next few weeks. As we identify and engage patients we will:
Perform the initial consultation, giving the patient a detailed tutorial regarding the Nu-V3 treatment
Prepare the virtual experience with the patient and run through our easy-to-access Virtual Visit
Deliver to the patient, our heart rate variability (HRV) device, which allows the patient to perform a simple 30 second diagnostic test, giving us a snapshot of the patient's level of health in advance of their first Nu-V3 treatment
These are the things we can do quickly so those at risk may understand that Nu-V3 is on its way to them ASAP.
The steps that allow Nu-Life to launch H.O.P.E. now.
Participate in our H.O.P.E. Initiative
There are a number of ways to participate in and support our initiative to help our protectors. If you would like to support us, please LIKE, COMMENT, OR SHARE on our LinkedIn and Facebook pages to help us spread the word.